TY - JOUR
T1 - The role of histone deacetylase inhibitors in metastatic breast cancer
AU - Zucchetti, Bruna
AU - Shimada, Andrea Kazumi
AU - Katz, Artur
AU - Curigliano, Giuseppe
PY - 2019/2
Y1 - 2019/2
N2 - Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
AB - Histone deacetylase inhibitors (HDACi) are a relatively new class of drug that plays an important role in the epigenetic and non-epigenetic regulation in cancer, inducing death, apoptosis and cell cycle arrest in cancer cells. Although HDACi are approved only for hematologic malignancies, there are several trials in the breast cancer setting with promising results. In this review, we summarize the latest studies with HDACi in breast cancer from the emerging data in the translational research until its possible applicability in the clinical practice.
KW - Breast cancer
KW - Epigenetic
KW - Histone acetylation
UR - http://www.scopus.com/inward/record.url?scp=85059302641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059302641&partnerID=8YFLogxK
U2 - 10.1016/j.breast.2018.12.001
DO - 10.1016/j.breast.2018.12.001
M3 - Review article
C2 - 30553187
AN - SCOPUS:85059302641
VL - 43
SP - 130
EP - 134
JO - Breast
JF - Breast
SN - 0960-9776
ER -